WO2025062372 - TYK2 INHIBITORS FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

National phase entry:
Publication Number WO/2025/062372
Publication Date 27.03.2025
International Application No. PCT/IB2024/059183
International Filing Date 20.09.2024
Title **
[English] TYK2 INHIBITORS FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
[French] INHIBITEURS DE TYK2 DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'UNE MALADIE INFLAMMATOIRE DE L'INTESTIN
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
SINGH, Namita
HARBISON, Carole Elizabeth
DURAIRAJ, Chandra
NGUYEN, Van Anh
HEAP, Graham Alastair Richard
XIA, Guliang
Priority Data
63/584,324   21.09.2023   US
63/551,960   09.02.2024   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
译文

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting3425
EPO Filing, Examination, Granting23719
Japan Filing, Examination, Granting2958
South Korea Filing, Examination, Granting3739
USA Filing, Examination, Granting11190
MasterCard Visa
Total: 45,031

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] Compounds, compositions thereof, and methods of using the same in dosing protocols for the inhibition of TYK2, and the treatment of inflammatory disorders including inflammatory bowel disease, including Crohn's disease or ulcerative colitis are described.[French] L'invention concerne des composés, des compositions de ceux-ci et des méthodes d'utilisation de ceux-ci dans des protocoles de dosage pour l'inhibition de TYK2, et le traitement de troubles inflammatoires comprenant une maladie intestinale inflammatoire, y compris la maladie de Crohn ou la rectocolite hémorragique.